The risk of cytomegalovirus infection in non-myeloablative peripheral stem cell transplantation compared with conventional bone marrow transplantation

Journal of Korean Medical Science

Volumn 19, Issue 2, 2004, Pages 172-176

  Oh, Suk Joong ^a   Lee, Kyoo Hyung ^b,c   Lee, Je Hwan ^b   Choi, Seong Jun ^b   Kim, Woo Kun ^b   Lee, Jung Shin ^b   Kim, Mi Na ^c  

^a School of Medicine   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

Bone Marrow Transplantation; Cytomegalovirus; Ganciclovir; Hematopoietic Stem Cell Transplantation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; GANCICLOVIR; METHOTREXATE; THYMOCYTE ANTIBODY;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; COLITIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION RISK; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 2342613405     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.2004.19.2.172     Document Type: Article

References (14)

1. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic disease. Blood 1998; 91: 756-63.
2. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, Chauncey TR, Gooley TA, Hegenbart U, Nash RA, Radich J, Wagner JL, Minor S, Appelbaum FR, Bensinger WI, Bryant E, Flowers ME, Georges GE, Grumet FC, Kiem HP, Torok-Storb B, Yu C, Blume KG, Storb RF. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-400.
3. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S, Giralt S, Ippoliti C, von Wolff B, Gajewski J, Donato M, Claxton D, Ueno N, Andersson B, Gee A, Champlin R. Transplant lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancy. J Clin Oncol 1998; 16: 2817-24.
4. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Korbling M, Keating M, Kantarjian H, Champlin R. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-6.
5. Park SH, Lee HG, Choi SC, Lee HR, Kim KH, Nam EM, Kim WS, Yoon SS, Kang WK, Kim SW, Park KC. Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation; analysis of risk factors. Korean J Hematop Stem cell Transplant 2001; 5: 23-31.
6. Mohty M, Faucher C, Vey N, Stoppa AM, Viret F, Chabbert I, Chabannon C, Bouabdallah R, Ladaique P, Collet L, Zandotti C, Maraninchi D, Blaise D. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. Bone Marrow Transplant 2000; 26: 251-5.
7. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P, Chakraverty R, Marshall T, Osman H, Mahendra P, Craddock C, Waldmann H, Hale G, Fegan CD, Yong K, Goldstone AH, Linch DC, Milligan DW. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357-63.
8. Nakai K, Kanda Y, Mineishi S, Saito T, Ohnishi M, Niiya H, Chizuka A, Takeuchi T, Matsubara H, Kami M, Makimoto A, Tanosaki R, Kunitoh H, Tobinai K, Takaue Y. Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin. Bone Marrow Transplant 2002; 29: 237-41.
9. Boeckh M, Bowden RA, Goodrich JM, Pettinger M, Meyers JD. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992; 80: 1358-64.
10. Junghanss C, Boeckh M, Carter R. Incidence of herpesvirus infections following nonmyeloablative allogeneic stem cell transplantation. Blood 2000; 96 (Suppl 1): 188a (Abstr. 805).
11. Nakamura R, Cortez K, Solomon S, Battiwalla M, Gill VJ, Hensel N, Childs R, Barrett AJ. High-does acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 30: 235-42.
12. Junghanss C, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, Chauncey T, McSweeney PA, Little MT, Corey L, Storb R. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002; 99: 1978-85.
13. Einsele H, Hebart H, Kaufmann-Schneider C, Sinzger C, Jahn G, Bader P, Klingebiel T, Dietz K, Loffler J, Bokemeyer C, Muller CA, Kanz L. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant 2000; 25: 757-63.
14. Trenschel R, Ross S, Husing J, Ottinger H, Elmaagacli A, Roggendorf M, Schaefer UW, Runde V. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT. Bone Marrow Transplant 2000; 25: 665-72.